The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 24, 2017

Filed:

Nov. 15, 2013
Applicants:

David S. Peabody, Albuquerque, NM (US);

Bryce Chackerian, Albuquerque, NM (US);

Carlee Ashley, Albuquerque, NM (US);

Eric Carnes, Albuquerque, NM (US);

Oscar Negrete, Livermore, CA (US);

Inventors:

David S. Peabody, Albuquerque, NM (US);

Bryce Chackerian, Albuquerque, NM (US);

Carlee Ashley, Albuquerque, NM (US);

Eric Carnes, Albuquerque, NM (US);

Oscar Negrete, Livermore, CA (US);

Assignees:

STC.UNM, Albuquerque, NM (US);

SANDIA CORPORATION, Albuquerque, NM (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/155 (2006.01); A61K 49/00 (2006.01); A61K 39/385 (2006.01); C12Q 1/70 (2006.01); C12N 7/00 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
A61K 39/155 (2013.01); G01N 33/56983 (2013.01);
Abstract

The invention relates to virus-like particles of bacteriophage MS2 (MS2 VLPs) displaying peptide epitopes or peptide mimics of epitopes of Nipah Virus envelope glycoprotein that elicit an immune response against Nipah Virus upon vaccination of humans or animals. Affinity selection on Nipah Virus-neutralizing monoclonal antibodies using random sequence peptide libraries on MS2 VLPs selected peptides with sequence similarity to peptide sequences found within the envelope glycoprotein of Nipah itself, thus identifying the epitopes the antibodies recognize. The selected peptide sequences themselves are not necessarily identical in all respects to a sequence within Nipah Virus glycoprotein, and therefore may be referred to as epitope mimics VLPs displaying these epitope mimics can serve as vaccine. On the other hand, display of the corresponding wild-type sequence derived from Nipah Virus and corresponding to the epitope mapped by affinity selection, may also be used as a vaccine.


Find Patent Forward Citations

Loading…